Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670982 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
A Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00670982: Completed Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
NCT00670982 is a Phase 2 study that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670982, a Phase 2 study, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
Interventions
- DRUG bevacizumab
- DRUG trastuzumab
- DRUG vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670982
The ClinicalTrials.gov registry entry for NCT00670982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harold J. Burstein, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bevacizumab is the first listed.
NCT00670982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670982 about?
NCT00670982 is a clinical study titled "Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer". The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
What is the current status of trial NCT00670982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2008-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00670982?
The interventions under investigation include: bevacizumab (DRUG), trastuzumab (DRUG), vinorelbine (DRUG).
Who is sponsoring clinical trial NCT00670982?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.